Intelligence Briefing · ~5 min read
Emerging Generic Competition in Psychiatry: Strategic Implications for Market Leaders
Psychiatry · SNRI
Type
Regulatory Context BriefingGenerated
Jul 23, 2026
Confidence
Moderate Confidence · 72%
Evidence
14 items
Sources
14
Key Takeaways
Leadership-ready summary — read in 5 minutes.
- Regulatory risk is concentrated around FDA AP — RISPERIDONE (SUPPL) (FDA). Entity match (ph health); Regulatory pathway relevance (nda). While the approval status is a positive step for PH HEALTH, the final approval and market entry timeline will be critical for assessing compliance and regulatory implications.
- Competitive pressure on Hikma: This approval allows Hikma to enter the market for Levomilnacipran, a treatment for major depressive disorder, potential.
- Competitive pressure on Alembic Pharmaceuticals: This approval allows Alembic to enter the market with a generic version of Haloperidol, potentially increasing competiti.
- Competitive pressure on Creekwood Pharmaceuticals: This approval allows Creekwood Pharmaceuticals to enter the ADHD market with a generic version of Atomoxetine, increasin.
Why It Matters
Strategic context for leadership and portfolio decision-making.
Regulatory risk is concentrated around FDA AP — RISPERIDONE (SUPPL) (FDA). Entity match (ph health); Regulatory pathway relevance (nda). While the approval status is a positive step for PH HEALTH, the final approval and market entry timeline will be critical for assessing compliance and regulatory implications.
Supporting Evidence
Evidence-backed items from the Humanexa intelligence graph.
Hikma's Levomilnacipran Hydrochloride ANDA210732 Receives AP Status
Psychiatry · SNRI
Source: Regulatory Approval
View evidenceFDA Grants Approval for Haloperidol ANDA214470 by Alembic
Psychiatry · Antipsychotic
Source: Regulatory Approval
View evidenceFDA Grants Approval for Atomoxetine Hydrochloride ANDA218875
Psychiatry · ADHD
Source: Regulatory Approval
View evidenceFDA Grants AP Status for Risperidone ANDA077494 Submission
Psychiatry · Antipsychotic
Source: Regulatory Approval
View evidence
Related Intelligence
Deep links to signals, insights, companies, and assets in the Humanexa graph.
Signals
- Hikma's Levomilnacipran Hydrochloride ANDA210732 Receives AP Status
Psychiatry · SNRI
- FDA Grants Approval for Haloperidol ANDA214470 by Alembic
Psychiatry · Antipsychotic
- FDA Grants Approval for Atomoxetine Hydrochloride ANDA218875
Psychiatry · ADHD
- FDA Grants AP Status for Risperidone ANDA077494 Submission
Psychiatry · Antipsychotic